This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study


Zheng, Ling, Mack, Wendy J., Dagerman, Karen S., Hsiao, John K., Lebowitz, Barry D., Lyketsos, Constantine G., Stroup, T. Scott, Sultzer, David L., Tariot, Pierre N., Vigen, Cheryl, Schneider, Lon S.


The American Journal Of Psychiatry, Volume: 166, No.: 5, Pages.: 583-590

Year of Publication



Objective: The second-generation antipsychotics are associated with metabolic abnormalities in patients with schizophrenia. Elderly patients with Alzheimer’s disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects.; Method: The authors assessed 186 male and 235 female Alzheimer’s disease outpatients from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) for changes in weight, waist circumference, blood pressure, fasting glucose, and lipids in relation to duration of second-generation antipsychotic use (i.e., olanzapine, quetiapine, and risperidone) throughout the 36-week trial, using logistic regression and mixed-effects models.; Results: Women showed significant weight gain (0.14 lb/week of use) while change was nonsignificant in men. Clinically significant weight gain (i.e., > or = 7% of body weight) was seen among patients with antipsychotic use < or = 12 weeks (odds ratio [OR]=1.56, 95% CI=0.53 to 4.58), between 12 and 24 weeks (OR=2.89, 95% CI=0.97 to 8.64), and > 24 weeks (OR=3.38, 95% CI=1.24 to 9.23) relative to patients who did not use antipsychotics during the trial. Olanzapine and quetiapine treatments were significantly associated with weight gain (0.12 and 0.14 lb/week, respectively). In addition, olanzapine was significantly associated with decreases in HDL cholesterol (-0.19 mg/dl/week) and increased girth (0.07 inches/week) relative to the placebo group. No treatment effects were noted for changes in blood pressure, glucose, and triglycerides.; Conclusion: Second-generation antipsychotic use was associated with weight gain in women, with olanzapine and quetiapine in particular, and with unfavorable change in HDL cholesterol and girth with olanzapine. The potential consequences of these effects suggest that patients with Alzheimer’s disease treated with second-generation antipsychotics should be monitored closely.;

Bibtex Citation

@article{Zheng_2009, doi = {10.1176/appi.ajp.2008.08081218}, url = {}, year = 2009, month = {may}, publisher = {American Psychiatric Publishing}, volume = {166}, number = {5}, pages = {583--590}, author = {Ling Zheng and Wendy J. Mack and Karen S. Dagerman and John K. Hsiao and Barry D. Lebowitz and Constantine G. Lyketsos and T. Scott Stroup and David L. Sultzer and Pierre N. Tariot and Cheryl Vigen and Lon S. Schneider}, title = {Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer's Disease Patients: The {CATIE}-{AD} Study}, journal = {American Journal of Psychiatry} }


adverse effects, aged, alzheimer disease, antipsychotic agents, benzodiazepines, chemically induced, dibenzothiazepines, double-blind method, drug monitoring, drug therapy, epidemiology, female, humans, male, mental disorders, metabolism, obesity, olanzapine, risperidone

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

Physical Health

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Antipsychotics and antidepressants